Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
Alector has raised $50.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2026.
Alector's investors include TCG Crossover, Hercules Capital, S32, AbbVie, Perceptive Advisors.
Alector is headquartered in South San Francisco, United States.
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
Alector is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alector — Funding & Investors." VCBacked, October 16, 2026, https://www.vcbacked.co/company/alector. Accessed November 13, 2026.
VCBacked. (2026). Alector — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/alector
{{cite web |title=Alector — Funding & Investors |url=https://www.vcbacked.co/company/alector |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Alector? Request a listing update